Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. Issue 4 (21st March 2019)

• Record Type: Journal Article
• Authors: Grass, George Daniel; Mills, Matthew N.; Ahmed, Kamran A.; Liveringhouse, Casey L.; Montejo, Michael J.; Robinson, Timothy J.; Chavez, Julio C.; Harrison, Louis B.; Kim, Sungjune
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 4(2019)
• Page Start: 886
• Page End: 893
• Publication Date: 2019-03-21
• Subjects: Radiation -- double hit or triple hit lymphoma -- molecular genetics; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1506586
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We investigated whether adding radiation (RT) to systemic therapy improved outcomes in early stage diffuse large B-cell lymphoma (DLBCL) patients with or without double- or triple-hit lymphoma (DHL/THL) biology. This analysis included 183 patients profiled with fluorescent in situ hybridization (FISH) for alterations in MYC, BLC2, and/or BCL6 . A total of 146 (80%) were non-DHL/THL, 27 (15%) were DHL, and 10 (6%) were THL. Systemic therapy without RT resulted in inferior freedom from relapse (FFR) (HR: 2.28; 95% CI, 1.10–4.77; p = .02). The median FFR for non-DHL/THL was not reached and was 33 and 22.3 months for DHL and THL, respectively; p < .001. Low-risk (R-IPI <2) DHL/THL patients treated with rituximab-based therapy had 3-year FFR rates of 11% and 71% for systemic therapy without and with RT, respectively; p = .04. No differences in overall survival were observed between the treatment groups. Treatment intensification with RT may improve early stage DHL/THL outcomes. Trial registration: ClinicalTrials.gov identifier: NCT02272686. Trial registration: ClinicalTrials.gov identifier: NCT02815397.